Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07434661

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07434661
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07434661. Randomized; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
Acronym
SAFE-HEART
Condition
Valve Disease, Heart
Condition
Atrial Fibrillation (AF)
Condition
Valve Replacement Surgery
Condition
Aortic Valve Surgery
Condition
Mitral Valve Annuloplasty
Condition
Mitral Valve Repair
Condition
Mitral Valve Surgery
Intervention (Drug)
Apixaban
Intervention (Drug)
Warfarin
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct07434661
Content hash
5c49c6603fc687a9318ee99b32e6bfba330b0226c80fb9fbd2ff4903f32c047b